The Intestinotrophic Effects of Glucagon-Like Peptide-2 in Relation to Intestinal Neoplasia
Research output: Contribution to journal › Review › Research › peer-review
Standard
The Intestinotrophic Effects of Glucagon-Like Peptide-2 in Relation to Intestinal Neoplasia. / Orhan, Adile; Gögenur, Ismail; Kissow, Hannelouise.
In: The Journal of clinical endocrinology and metabolism, Vol. 103, No. 8, 2018, p. 2827-2837 .Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The Intestinotrophic Effects of Glucagon-Like Peptide-2 in Relation to Intestinal Neoplasia
AU - Orhan, Adile
AU - Gögenur, Ismail
AU - Kissow, Hannelouise
PY - 2018
Y1 - 2018
N2 - Context: Glucagon-like peptide-2 (GLP-2) is a gastrointestinal hormone with intestinotrophic and anti-apoptotic effects. The hormone's therapeutic potential in intestinal diseases and relation to intestinal neoplasia have raised great interest among researchers. This paper reviews and discusses published experimental and clinical studies concerning the growth-stimulating and anti-apoptotic effects of GLP-2 in relation to intestinal neoplasia.Evidence acquisition: The data used in this narrative review were collected through literature research in PubMed using English keywords. All studies to date examining GLP-2's relation to intestinal neoplasms have been reviewed in this article, as the studies on the matter are sparse.Evidence synthesis: GLP-2 has been found to stimulate intestinal growth through secondary mediators and through the involvement of Akt phosphorylation. Studies on rodents have shown that exogenously administered GLP-2 increases the growth and incidence of adenomas in the colon, suggesting that GLP-2 may play a significant role in the progression of intestinal tumours. Clinical studies have found that exogenous GLP-2 treatment is well-tolerated for up to 30 months, but the tolerability for even longer periods of treatment has not been examined.Conclusion: Exogenous GLP-2 is currently available as teduglutide for the treatment of short bowel syndrome. However, the association between exogenous GLP-2 treatment and intestinal neoplasia in humans has not been fully identified. This leads to a cause for concern regarding the later risk of the development or progression of intestinal tumours with long-term GLP-2 treatment. Therefore, further research regarding GLP-2's potential relation to intestinal cancers is needed.
AB - Context: Glucagon-like peptide-2 (GLP-2) is a gastrointestinal hormone with intestinotrophic and anti-apoptotic effects. The hormone's therapeutic potential in intestinal diseases and relation to intestinal neoplasia have raised great interest among researchers. This paper reviews and discusses published experimental and clinical studies concerning the growth-stimulating and anti-apoptotic effects of GLP-2 in relation to intestinal neoplasia.Evidence acquisition: The data used in this narrative review were collected through literature research in PubMed using English keywords. All studies to date examining GLP-2's relation to intestinal neoplasms have been reviewed in this article, as the studies on the matter are sparse.Evidence synthesis: GLP-2 has been found to stimulate intestinal growth through secondary mediators and through the involvement of Akt phosphorylation. Studies on rodents have shown that exogenously administered GLP-2 increases the growth and incidence of adenomas in the colon, suggesting that GLP-2 may play a significant role in the progression of intestinal tumours. Clinical studies have found that exogenous GLP-2 treatment is well-tolerated for up to 30 months, but the tolerability for even longer periods of treatment has not been examined.Conclusion: Exogenous GLP-2 is currently available as teduglutide for the treatment of short bowel syndrome. However, the association between exogenous GLP-2 treatment and intestinal neoplasia in humans has not been fully identified. This leads to a cause for concern regarding the later risk of the development or progression of intestinal tumours with long-term GLP-2 treatment. Therefore, further research regarding GLP-2's potential relation to intestinal cancers is needed.
U2 - 10.1210/jc.2018-00655
DO - 10.1210/jc.2018-00655
M3 - Review
C2 - 29741675
VL - 103
SP - 2827
EP - 2837
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 8
ER -
ID: 197962069